AI Deals and Investments
  • All Technology
  • AI
  • Autonomy
  • B2B Growth
  • Big Data
  • BioTech
  • ClimateTech
  • Consumer Tech
  • Crypto
  • Cybersecurity
  • DevOps
  • Digital Marketing
  • Ecommerce
  • EdTech
  • Enterprise
  • FinTech
  • GovTech
  • Hardware
  • HealthTech
  • HRTech
  • LegalTech
  • Nanotech
  • PropTech
  • Quantum
  • Robotics
  • SaaS
  • SpaceTech
AllNewsDealsSocialBlogsVideosPodcastsDigests

AI Pulse

EMAIL DIGESTS

Daily

Every morning

Weekly

Sunday recap

NewsDealsSocialBlogsVideosPodcasts
TandemAI Secures $22M Series A Extension to Boost AI‑Driven Drug Discovery
Series A

TandemAI Secures $22M Series A Extension to Boost AI‑Driven Drug Discovery

•November 14, 2025
•Nov 14, 2025
0

Participants

TandemAI

TandemAI

company

KHK Partners

KHK Partners

investor

VCI Global

VCI Global

investor

Why It Matters

The infusion of $22 million highlights strong market confidence in AI‑powered drug discovery, potentially speeding up candidate identification and giving TandemAI a competitive edge in a rapidly evolving biotech landscape.

Deal Summary

TandemAI, a New York‑based drug discovery firm, announced a $22 million Series A extension round. The funding, led by KHK Fund and V‑Capital among other investors, will be used to expand operations and accelerate R&D on its AI‑powered SaaS platform.

0

Comments

Want to join the conversation?

Loading comments...